Shares of Hims & Hers Health surged 6.8% to $27.94 on June 1, extending a blistering multi-week rally that has lifted the stock roughly 17% in just five trading sessions, as a wave of bullish analyst initiations reframes the company's growth story around weight-loss drugs and digital health. Hims & Hers Surges 17% in Five Days as Wall Street Loads Up on Upgrades — But Can the Business Outgrow Its Margin Problem?
Shares of Hims & Hers Health rocketed to $27.94, up 6.8% in a single session and roughly 17% over five trading days, as investors chase a stock now backed by a chorus of bullish analyst calls. The rally forces a sharp question: is the optimism priced correctly, or are buyers ignoring a messy transition underneath?
• JPMorgan and Canaccord Are Betting on a $33 Stock, but the Last Quarter Was Ugly
JPMorgan analyst Cory Carpenter initiated coverage with an Overweight rating and a $35 price target , later trimmed to $33 after a mixed Q1 report . Canaccord raised its target to $32 with a Buy rating , while Bank of America cut to $30 with a Neutral rating . At $27.94, HIMS still trades below every major target — which is fueling the chase — but the gap is narrowing fast.
• Revenue Grew Just 4% and the Company Lost Money Last Quarter
Hims & Hers posted Q1 2026 revenue of $608.1 million, up only 4% year over year, missing consensus . Gross margin — the share of revenue left after production costs — slipped to 65% from 73%, and adjusted EBITDA (a rough measure of operating profit) fell to $44.3 million from $91.1 million . The culprit: a strategic shift away from cheaper, self-compounded weight-loss drugs toward pricier branded alternatives from Novo Nordisk . That swap is legally safer but financially painful in the short run.
• The International Bet Is Growing Fast From a Tiny Base
International revenue surged 969% year over year to $78.2 million , boosted by a $1.15 billion acquisition of Australia-based Eucalyptus . Management has set a long-term target of $6.5 billion in 2030 revenue — more than double the raised 2026 guidance of $2.8–$3 billion . That ambition underpins the bull case, but overseas markets carry execution risk and the company already holds roughly $1 billion in convertible debt .
• Regulatory and Legal Clouds Haven't Cleared
The FDA is investigating Hims & Hers' compounded weight-loss practices, and the SEC has opened a probe into related disclosures . Securities class-action lawsuits tied to the original Novo Nordisk partnership collapse remain unresolved . Any adverse ruling could crimp the very revenue stream analysts are banking on.
Bottom line: Wall Street's targets give HIMS roughly 18–25% further upside, but that math depends on a margin recovery that hasn't started yet and regulatory risks that haven't resolved. Buyers at $28 are paying for execution that remains unproven.